Detalhe da pesquisa
1.
Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol.
Lancet Oncol
; 24(5): 443-456, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37142371
2.
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.
Lancet
; 399(10323): 447-460, 2022 01 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-34953525
3.
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial.
Lancet Oncol
; 23(7): 919-930, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35690073
4.
Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476).
Int J Cancer
; 151(3): 422-434, 2022 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35411939
5.
Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial.
PLoS Med
; 19(6): e1003998, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35671327
6.
Low probability of disease cure in advanced ovarian carcinomas before the PARP inhibitor era.
Br J Cancer
; 127(1): 79-83, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35361918
7.
Weekly versus tri-weekly paclitaxel with carboplatin for first-line treatment in women with epithelial ovarian cancer.
Cochrane Database Syst Rev
; 2: CD012007, 2022 Feb 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-35188221
8.
Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial.
Lancet Oncol
; 22(2): 277-288, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33357510
9.
Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data.
Lancet
; 396(10260): 1422-1431, 2020 10 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-33002431
10.
Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial.
Lancet
; 396(10260): 1413-1421, 2020 10 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-33002429
11.
Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial.
Lancet Oncol
; 21(7): 969-977, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32615110
12.
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial.
Lancet
; 394(10214): 2084-2095, 2019 12 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31791688
13.
Microbial Translocation Does Not Drive Immune Activation in Ugandan Children Infected With HIV.
J Infect Dis
; 219(1): 89-100, 2019 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30107546
14.
Quality of life with cediranib in relapsed ovarian cancer: The ICON6 phase 3 randomized clinical trial.
Cancer
; 123(14): 2752-2761, 2017 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28339098
15.
Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial.
Lancet
; 387(10023): 1066-1074, 2016 Mar 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-27025186
16.
Effect of diurnal variation, CYP2B6 genotype and age on the pharmacokinetics of nevirapine in African children.
J Antimicrob Chemother
; 72(1): 190-199, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27707991
17.
Progression-free survival in the ICON8 trial - Authors' reply.
Lancet
; 396(10253): 757, 2020 09 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32919511
18.
The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children.
Br J Clin Pharmacol
; 82(1): 185-98, 2016 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-26991336
19.
The Cost-Effectiveness of Bevacizumab in Advanced Ovarian Cancer Using Evidence from the ICON7 Trial.
Value Health
; 19(4): 431-9, 2016 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-27325335
20.
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.
Lancet Oncol
; 16(8): 928-36, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-26115797